Literature DB >> 31392198

Diagnostic tools in late onset Pompe disease (LOPD).

Olimpia Musumeci1, Antonio Toscano1.   

Abstract

Pompe disease is a rare metabolic disorder due to deficiency of the lysosomal acid alpha-glucosidase (GAA) that causes glycogen accumulation in all tissues with a predominant involvement of skeletal muscle. The late onset form of Pompe disease (LOPD) is characterized by a progressive weakness of proximal and axial muscles, often mimicking limb-girdle muscular dystrophies or inflammatory myopathies, with respiratory distress mainly due to a diaphragmatic weakness. Diagnostic delay is still common, and clinicians need a high index of suspicion to recognize this condition because the disorder is quite rare, the clinical spectrum is wide, and signs and symptoms are not distinguishable from those in other neuromuscular disorders that present in a similar fashion. Diagnostic laboratory tests are quite fast and reliable to detect the enzymatic deficiency. Enzyme replacement therapy has been available for several years, and other new therapeutic strategies such as gene therapy are underway. Here, we discuss the main diagnostic tools currently used for the evaluation of patients with suspected LOPD.

Entities:  

Keywords:  GAA enzyme assays; LOPD screening test; PAS-positive lymphocytes; Pompe disease diagnosis; blood smear; dried blood spots

Year:  2019        PMID: 31392198      PMCID: PMC6642940          DOI: 10.21037/atm.2019.06.60

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  40 in total

1.  Characterization of the human lysosomal alpha-glucosidase gene.

Authors:  L H Hoefsloot; M Hoogeveen-Westerveld; A J Reuser; B A Oostra
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.

Authors:  B Winchester; D Bali; O A Bodamer; C Caillaud; E Christensen; A Cooper; E Cupler; M Deschauer; K Fumić; M Jackson; P Kishnani; L Lacerda; J Ledvinová; A Lugowska; Z Lukacs; I Maire; H Mandel; E Mengel; W Müller-Felber; M Piraud; A Reuser; T Rupar; I Sinigerska; M Szlago; F Verheijen; O P van Diggelen; B Wuyts; E Zakharova; J Keutzer
Journal:  Mol Genet Metab       Date:  2007-12-19       Impact factor: 4.797

3.  Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.

Authors:  M A Kroos; R J Pomponio; M L Hagemans; J L M Keulemans; M Phipps; M DeRiso; R E Palmer; M G E M Ausems; N A M E Van der Beek; O P Van Diggelen; D J J Halley; A T Van der Ploeg; A J J Reuser
Journal:  Neurology       Date:  2007-01-09       Impact factor: 9.910

4.  Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

Authors:  C Angelini; C Semplicini; S Ravaglia; B Bembi; S Servidei; E Pegoraro; M Moggio; M Filosto; E Sette; G Crescimanno; P Tonin; R Parini; L Morandi; G Marrosu; G Greco; O Musumeci; G Di Iorio; G Siciliano; M A Donati; F Carubbi; M Ermani; T Mongini; A Toscano
Journal:  J Neurol       Date:  2011-11-12       Impact factor: 4.849

5.  Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre.

Authors:  G Anderson; V V Smith; M Malone; N J Sebire
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

6.  Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited.

Authors:  B G H Schoser; J Müller-Höcker; R Horvath; K Gempel; D Pongratz; H Lochmüller; W Müller-Felber
Journal:  Neuropathol Appl Neurobiol       Date:  2007-06-15       Impact factor: 8.090

7.  Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid alpha-glucosidase".

Authors:  Youichi Tajima; Fumiko Matsuzawa; Sei-Ichi Aikawa; Toshika Okumiya; Michiru Yoshimizu; Takahiro Tsukimura; Masahiko Ikekita; Seiichi Tsujino; Akihiko Tsuji; Tim Edmunds; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2007-09-06       Impact factor: 3.172

Review 8.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

9.  Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.

Authors:  Wolfgang Müller-Felber; Rita Horvath; Klaus Gempel; Teodor Podskarbi; Yoon Shin; Dieter Pongratz; Maggie C Walter; Martina Baethmann; Beate Schlotter-Weigel; Hanns Lochmüller; Benedikt Schoser
Journal:  Neuromuscul Disord       Date:  2007-07-23       Impact factor: 4.296

10.  PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease.

Authors:  Marloes L C Hagemans; Rolinda L Stigter; Carine I van Capelle; Nadine A M E van der Beek; Leon P F Winkel; Laura van Vliet; Wim C J Hop; Arnold J J Reuser; Auke Beishuizen; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2010-01-27       Impact factor: 4.982

View more
  1 in total

1.  Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease.

Authors:  Aniko Gal; Zoltán Grosz; Beata Borsos; Ildikó Szatmari; Agnes Sebők; Laszló Jávor; Veronika Harmath; Katalin Szakszon; Livia Dezsi; Eniko Balku; Zita Jobbagy; Agnes Herczegfalvi; Zsuzsanna Almássy; Levente Kerényi; Maria Judit Molnar
Journal:  Life (Basel)       Date:  2021-05-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.